One of the vaccine against the new coronavirus infection developed in the State research center of Virology and biotechnology “Vector” of Rospotrebnadzor, is intended for intranasal, it will drip into the nose. This was told in the film Naila Asker-zade “Threat virus. The vaccine” on TV channel “Russia 1”, the General Director of the centre of Rinat Maksyutov.

According to him, already running full-scale preclinical trial data of drugs in terms of effectiveness and safety. According to the optimistic forecasts of the first clinical research for the first vaccine in the “Vector” is calculated to begin in late June — early July and be completed in mid-September.

In laboratory tests infection with the novel coronavirus were carried out, in particular, the lower primates, said native. The results obtained at that model the infection of coronavirus COVID-19, as a person. There are a significant number of asymptomatic cases, when the virus can be controlled only by warusawithana, the individual temperature is used and the x-ray machine to monitor possible changes in the lungs.

All animals, according to Maksudova, very well postponed the introduction of vaccines “Vector”: there were no fevers, no adverse reactions.

an Additional acceleration testing of vaccines is not required, says the General Director of “Vector”: the need not to harm, and not to stick a useless product. Clinical study developed at the center for vaccine COVID-19 will be conducted on volunteers of both sexes aged 18 to 60 years. People, already ill with the novel coronavirus, to be volunteers in clinical trials of vaccines will not. Vaccine research from COVID-19 children can begin in early 2021.

the Head of Rospotrebnadzor Anna Popova in the film said: in Russia very much hope that I will get the vaccine from negative experiences.about coronavirus in time, before the second wave of the disease. According to her, every year a significant number of people carry SARS, caused by different coronaviruses. Today we can exactly say past seasonal coronavirus does not give cross-immunity from COVID-19.